From Seekingalpha · · 30s
TL;DR: Cogent: Valuation Leaves No Room for Error
Cogent's promising data faces tight valuation margins.
Cogent Biosciences' bezuclastinib shows strong results but trading near fair value with little room for error. Cogent's promising data faces tight valuation margins. Cogent Biosciences trades near $29.83 fair value with little room for error. Bezuclastinib's pivotal GIST trial showed 16.5 months median progression-free survival versus 9.2 months for sunitinib. Three FDA decisions starting November 30, 2026, and $791.1 million cash balance support commercialization.
- Cogent's valuation
- Bezuclastinib trial results
- FDA decisions and cash balance
Read the story version — the same reporting as a swipeable deck of 3 cards.